1. Home
  2. Medical News
  3. Oncology
advertisement

Spark-like CD8+ T Cells Linked to Anti-PD-1 Outcomes in NSCLC

Highlighted CD8 T cell within illustrated nonsmall cell lung cancer tissue after antiPD1 treatment
11/20/2026

Key Takeaways

  • Surgically sampled NSCLC tumors after anti-PD-1–based therapy showed enrichment of Spark-like CD8+ T cells among responders.
  • Greater CD8A+CD39+CD45RO+ staining intensity was significantly associated with partial response versus stable disease.
  • Higher intensity of the three-marker phenotype was associated with longer overall survival, including after adjustment for disease stage and PD-L1 tumor proportion score.
  • A derived expression signature was associated with survival in its training cohort and three external expression cohorts, not validated as a treatment-response test.
Responses to anti–programmed death-1 (PD-1)–based therapy vary among patients with non-small cell lung cancer (NSCLC). Whether specific functional states of tumor-infiltrating CD8+ T cells, beyond their overall abundance, accompany response and survival in treated tumors remains uncertain.

Li and colleagues combined retrospective tumor profiling, observational clinical associations, spatial transcriptomics, and expression-based survival modeling in their Frontiers in Immunology study of Spark-like CD8+ T cells in NSCLC. Single-cell RNA sequencing (scRNA-seq) dataset GSE207422 contained 14 surgical NSCLC samples obtained after neoadjuvant anti-PD-1–based therapy; response was classified using pathological response and Response Evaluation Criteria in Solid Tumors. Spark-like cells were defined as a marker- and core-module-gated CD8+ functional state, not a separate lineage. A distinct multiplex immunohistochemistry (mIHC) cohort comprised 100 primary surgical tumors collected after anti-PD-1 plus chemotherapy at Shandong Provincial Hospital, China. CD8A/CD39/CD45RO staining served as a surrogate for the transcriptomic state in analyses of treatment response and overall survival. Investigators also mapped spatial signals and trained a 14-gene survival score in The Cancer Genome Atlas (TCGA) NSCLC cohort (TCGA-NSCLC), assessing it in Gene Expression Omnibus (GEO) datasets GSE37745, GSE41271, and GSE72094.

Spark-like CD8+ T cells were enriched in post-treatment scRNA-seq samples from responders, whereas naive/central memory and exhausted states predominated among nonresponders. In the separate mIHC cohort, greater CD8A+CD39+CD45RO+ intensity was associated with partial response versus stable disease (p = 0.0075). Higher versus lower intensity was also associated with longer overall survival (log-rank p < 0.001). According to the investigators, the survival association persisted in multivariable Cox analysis accounting for disease stage and programmed death-ligand 1 (PD-L1) tumor proportion score.

The expression-derived score separated overall-survival risk groups in the TCGA-NSCLC training cohort and all three GEO validation cohorts. Its survival association was also reported after adjustment for age, sex, and tumor stage. Spatial mapping placed inferred Spark-like signals alongside M1 macrophage signals, indicating co-localization rather than demonstrating physical interaction.

Both clinical response analyses used tumors obtained after treatment, so their associations do not establish individual response prediction before therapy begins. The three-marker mIHC phenotype is a surrogate for the fuller single-cell program, not an interchangeable measurement or a standardized clinical assay. Retrospective associations cannot establish that Spark-like cells cause response. The external bulk-expression cohorts assess survival prognosis, not prospective selection for anti-PD-1 treatment.

Li and colleagues described Spark-like CD8+ T cells are clinically relevant to anti-PD-1 response in NSCLC. Because the response and staining analyses used post-treatment tumors and the expression score assessed prognosis, neither finding established a pretreatment predictive test.

Clinician Questions

How were Spark-like CD8+ T cells defined in anti-PD-1–treated NSCLC tumors?

In single-cell profiles of NSCLC surgical tumors obtained after neoadjuvant anti-PD-1–based treatment, investigators scored relatively high CD2, ENTPD1, and PTPRC and relatively low CCR7 and IL7R. They designated clusters Spark-like when the five-marker composite phenotype score was in the top 10% and the Spark_Core module score was at least the median. This gate identified an overlapping CD8+ functional state, not a completely separate lineage; it differs from the three-marker mIHC surrogate.

What did TNF, ENTPD1, and IL2 knockout simulations show about Spark-like T cells in NSCLC?

For Spark-like CD8+ T cells profiled from NSCLC tumors after anti-PD-1–based treatment, in silico gene-knockout analysis nominated TNF, ENTPD1, and IL2 as candidate cooperative regulators of the Spark_Core functional module. The simulations did not experimentally establish causal function, physical interactions, or therapeutic benefit.

This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free